Key result
Study evaluates CRT and MAGGIC-HF score for long-term prognosis but lacks specific clinical results.
Why the study?
Cardiac resynchronization therapy is a significant treatment option in HF patients not responding to optimal medical treatment, but its long-term prognosis and relationship with the MAGGIC-HF risk score required evaluation.
What is the long-term prognosis of cardiac resynchronization therapy (CRT) and its relationship with the MAGGIC-HF risk score in heart failure patients?
Cohort (n=110)
What is the long-term prognosis of cardiac resynchronization therapy (CRT) and its relationship with the MAGGIC-HF risk score in heart failure patients?
In heart failure patients undergoing CRT, 2-year survival was significantly associated with higher left ventricular ejection fraction and lower pulmonary artery systolic pressure.
Answers are grounded in this paper and cite their sources.
MAGGIC-HF utility in CRT recipients remains unproven; leaves open need for dedicated validation before risk-stratification use.
Objectives: Cardiac resynchronization therapy (CRT) has recently become a significant treatment option in patients with heart failure (HF), who do not respond to optimal medical treatment.In this study, we aimed to evaluate the long-term prognosis of CRT and to determine the relationship between the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC-HF) risk score and CRT. Materials and Methods:One hundred and ten consecutive patients who underwent CRT between 2015 and 2019 were analyzed retrospectively.Baseline characteristics of the patients were recorded and clinical parameters including laboratory, electrocardiographic and echocardiographic were compared before CRT implantation and during patient follow-up.The patients were classified as surviving patients and patients without survival according to the 2-year clinical outcome.The improvement in echocardiographic parameters observed at the 6 th month after CRT in surviving patients was defined as a positive response to CRT. Results:The patients with survival had lower pulmonary artery systolic pressure (PASP) (34.66±18.31vs 46.50±15.86p=0.01) and higher left ventricular ejection fraction (LVEF) than patients without survival (27.00±5.86vs 23.89±5.32p=0.04).
No takes yet. Share an insight, caveat, or question.
Nar et al. (2021) conducted a cohort in Heart failure (n=110). Cardiac resynchronization therapy (CRT) and MAGGIC-HF risk score vs. Surviving vs non-surviving patients at 2 years was evaluated on 2-year survival and 6-month echocardiographic response (LVEF and PASP) (p=0.04). Cardiac resynchronization therapy survivors at 2 years had higher LVEF (27.00% vs 23.89%, p=0.04) and lower PASP (34.66 vs 46.50, p=0.01) than non-survivors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: